- Home
- O vs TAK Comparison
O vs TAK Comparison
Compare O & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- O
- TAK
- Stock Information
- Founded
- O 1969
- TAK 1781
- Country
- O United States
- TAK Japan
- Employees
- O N/A
- TAK N/A
- Industry
- O Real Estate Investment Trusts
- TAK Biotechnology: Pharmaceutical Preparations
- Sector
- O Real Estate
- TAK Health Care
- Exchange
- O Nasdaq
- TAK Nasdaq
- Market Cap
- O 48.7B
- TAK 42.2B
- IPO Year
- O N/A
- TAK N/A
- Fundamental
- Price
- O $57.11
- TAK $14.98
- Analyst Decision
- O Hold
- TAK
- Analyst Count
- O 14
- TAK 0
- Target Price
- O $62.12
- TAK N/A
- AVG Volume (30 Days)
- O 5.9M
- TAK 1.5M
- Earning Date
- O 05-05-2025
- TAK 05-08-2025
- Dividend Yield
- O 5.54%
- TAK 3.95%
- EPS Growth
- O N/A
- TAK 15.39
- EPS
- O 0.98
- TAK 0.83
- Revenue
- O $5,278,935,000.00
- TAK $29,124,927,177.00
- Revenue This Year
- O $3.43
- TAK $8.53
- Revenue Next Year
- O $5.31
- TAK N/A
- P/E Ratio
- O $58.29
- TAK $34.51
- Revenue Growth
- O 29.34
- TAK 9.83
- 52 Week Low
- O $50.65
- TAK $12.58
- 52 Week High
- O $64.88
- TAK $15.31
- Technical
- Relative Strength Index (RSI)
- O 53.73
- TAK 57.24
- Support Level
- O $56.51
- TAK $14.75
- Resistance Level
- O $58.27
- TAK $15.17
- Average True Range (ATR)
- O 0.89
- TAK 0.18
- MACD
- O 0.02
- TAK -0.08
- Stochastic Oscillator
- O 57.79
- TAK 40.18
About O Realty Income Corporation
Realty Income owns roughly 15,400 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, gaming, office, manufacturing, and distribution properties, which make up roughly 20% of revenue.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.